Genitourinary Cancers Metastatic Castration-Resistant Prostate Cancer: Tumor Mutational Burden and Therapy Response
Genitourinary Cancers ASCO GU 2024: Cabozantinib and Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
Genitourinary Cancers Racial and Ethnic Disparities in Hormone Therapy Receipt Among Patients With Prostate Cancer
Genitourinary Cancers ASCO GU 2023: Rucaparib or Physician’s Choice in Metastatic Castration-Resistant Prostate Cancer
Genitourinary Cancers ASCO GU 2023: Talazoparib Plus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Genitourinary Cancers ASTRO 2022: Differences in Physician Assessment of Sexual Dysfunction in Women and Men Receiving Brachytherapy for Genitourinary Cancers
Genitourinary Cancers Radiopharmaceuticals for Treatment of Metastatic Castration-Resistant Prostate Cancer
Genitourinary Cancers ESMO 2022: COSMIC-313 Trial of Triplet Therapy in Advanced Renal Cell Carcinoma
Genitourinary Cancers ESMO 2022: Adjuvant Atezolizumab for Patients With RCC at Increased Risk of Recurrence After Resection
Genitourinary Cancers Neoadjuvant Enfortumab Vedotin-ejfv in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer
Genitourinary Cancers New Genetic Risk Score May Aid in Predicting the Likelihood of Developing, Dying From Prostate Cancer
Genitourinary Cancers Treatment-Related Regret Among Men With Localized Prostate Cancer: Examining Potential Factors
Genitourinary Cancers Radiopharmaceuticals for Treatment of Metastatic Castration-Resistant Prostate Cancer
